Galmed Pharmaceuticals Stock Performance
| GLMD Stock | USD 0.54 0.03 5.26% |
The company retains a Market Volatility (i.e., Beta) of 1.32, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Galmed Pharmaceuticals will likely underperform. At this point, Galmed Pharmaceuticals has a negative expected return of -0.62%. Please make sure to check out Galmed Pharmaceuticals' treynor ratio, accumulation distribution, price action indicator, as well as the relationship between the potential upside and day median price , to decide if Galmed Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Galmed Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's primary indicators remain rather sound which may send shares a bit higher in March 2026. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
Last Split Factor 1:12 | Last Split Date 2024-08-30 |
1 | Galmed Pharmaceuticals Q3 Earnings Snapshot | 11/26/2025 |
2 | Galmed Issues CEO Letter to Shareholders | 12/01/2025 |
3 | Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals Rezdiffra for MASH | 12/04/2025 |
4 | Will Galmed Pharmaceuticals Ltd. stock outperform tech sector in 2025 - Weekly Market Report Stock Portfolio Risk Control - Bollywood Helpline | 12/17/2025 |
5 | Is Galmed Pharmaceuticals Ltd. stock worth buying before Fed action - Earnings Risk Report Stepwise Trade Signal Implementation - ulpravda.ru | 01/08/2026 |
6 | Chart Watch Will Galmed Pharmaceuticals Ltd benefit from government policy - Weekly Investment Report Smart Investment Allocation Insights - baoquankhu1.vn | 01/12/2026 |
7 | Galmed Pharmaceuticals receives Nasdaq bid price deficiency notice | 01/30/2026 |
| Begin Period Cash Flow | 3 M | |
| Total Cashflows From Investing Activities | -1.1 M |
Galmed Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 85.00 in Galmed Pharmaceuticals on November 24, 2025 and sell it today you would lose (31.00) from holding Galmed Pharmaceuticals or give up 36.47% of portfolio value over 90 days. Galmed Pharmaceuticals is currently does not generate positive expected returns and assumes 5.0549% risk (volatility on return distribution) over the 90 days horizon. In different words, 45% of stocks are less volatile than Galmed, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Galmed Pharmaceuticals Target Price Odds to finish over Current Price
The tendency of Galmed Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.54 | 90 days | 0.54 | roughly 97.0 |
Based on a normal probability distribution, the odds of Galmed Pharmaceuticals to move above the current price in 90 days from now is roughly 97.0 (This Galmed Pharmaceuticals probability density function shows the probability of Galmed Stock to fall within a particular range of prices over 90 days) .
Galmed Pharmaceuticals Price Density |
| Price |
Predictive Modules for Galmed Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Galmed Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Galmed Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Galmed Pharmaceuticals is not an exception. The market had few large corrections towards the Galmed Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Galmed Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Galmed Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.95 | |
β | Beta against Dow Jones | 1.32 | |
σ | Overall volatility | 0.16 | |
Ir | Information ratio | -0.17 |
Galmed Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Galmed Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Galmed Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Galmed Pharmaceuticals generated a negative expected return over the last 90 days | |
| Galmed Pharmaceuticals has high historical volatility and very poor performance | |
| Galmed Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Galmed Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (7.52 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Galmed Pharmaceuticals currently holds about 22.4 M in cash with (5.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.89, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Galmed Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Latest headline from seekingalpha.com: Galmed Pharmaceuticals receives Nasdaq bid price deficiency notice |
Galmed Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Galmed Stock often depends not only on the future outlook of the current and potential Galmed Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Galmed Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 930.8 K | |
| Cash And Short Term Investments | 15.3 M |
Galmed Pharmaceuticals Fundamentals Growth
Galmed Stock prices reflect investors' perceptions of the future prospects and financial health of Galmed Pharmaceuticals, and Galmed Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Galmed Stock performance.
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.21 | ||||
| Current Valuation | (4 M) | ||||
| Shares Outstanding | 6.58 M | ||||
| Price To Earning | (6.79) X | ||||
| Price To Book | 0.42 X | ||||
| EBITDA | (7.42 M) | ||||
| Net Income | (7.52 M) | ||||
| Cash And Equivalents | 22.4 M | ||||
| Cash Per Share | 0.89 X | ||||
| Total Debt | 2.17 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 8.48 X | ||||
| Book Value Per Share | 3.49 X | ||||
| Cash Flow From Operations | (5.88 M) | ||||
| Earnings Per Share | (3.44) X | ||||
| Market Capitalization | 3.56 M | ||||
| Total Asset | 18.5 M | ||||
| Retained Earnings | (200.47 M) | ||||
| Working Capital | 13.95 M | ||||
| Current Asset | 23.38 M | ||||
| Current Liabilities | 2.54 M | ||||
About Galmed Pharmaceuticals Performance
By analyzing Galmed Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Galmed Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Galmed Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Galmed Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 1.1 K | 951 | |
| Return On Tangible Assets | (0.37) | (0.38) | |
| Return On Capital Employed | (0.35) | (0.36) | |
| Return On Assets | (0.37) | (0.38) | |
| Return On Equity | (0.53) | (0.50) |
Things to note about Galmed Pharmaceuticals performance evaluation
Checking the ongoing alerts about Galmed Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Galmed Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Galmed Pharmaceuticals generated a negative expected return over the last 90 days | |
| Galmed Pharmaceuticals has high historical volatility and very poor performance | |
| Galmed Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Galmed Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (7.52 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Galmed Pharmaceuticals currently holds about 22.4 M in cash with (5.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.89, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Galmed Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Latest headline from seekingalpha.com: Galmed Pharmaceuticals receives Nasdaq bid price deficiency notice |
- Analyzing Galmed Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Galmed Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Galmed Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Galmed Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Galmed Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Galmed Pharmaceuticals' stock. These opinions can provide insight into Galmed Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Galmed Stock analysis
When running Galmed Pharmaceuticals' price analysis, check to measure Galmed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galmed Pharmaceuticals is operating at the current time. Most of Galmed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Galmed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galmed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Galmed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |